{"id":"NCT02718326","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)","officialTitle":"A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-29","primaryCompletion":"2018-08-06","completion":"2019-07-16","firstPosted":"2016-03-24","resultsPosted":"2019-11-21","lastUpdate":"2020-07-30"},"enrollment":402,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Nonproliferative Diabetic Retinopathy"],"interventions":[{"type":"DRUG","name":"Intravitreal aflibercept injection [IAI]","otherNames":["EYLEA® (aflibercept) Injection","BAY86-5321"]},{"type":"DRUG","name":"Sham","otherNames":[]}],"arms":[{"label":"Dosing regimen 1","type":"EXPERIMENTAL"},{"label":"Dosing regimen 2","type":"EXPERIMENTAL"},{"label":"Dosing regimen 3","type":"SHAM_COMPARATOR"}],"summary":"The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).\n\nThe secondary objectives of the study are:\n\n* To characterize the safety of IVT aflibercept in patients with moderately severe to severe NPDR\n* To determine if IVT aflibercept will prevent the worsening of diabetic retinopathy and reduce the incidence of DME\n* To determine the anatomic effects of IVT aflibercept in patients with moderately severe to severe NPDR","primaryOutcome":{"measure":"Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups","timeFrame":"At Week 24","effectByArm":[{"arm":"Sham Treatment","deltaMin":6,"sd":null},{"arm":"Intravitreal Aflibercept Injection (IAI) 2Q16","deltaMin":61.5,"sd":null},{"arm":"Intravitreal Aflibercept Injection (IAI) 2Q8","deltaMin":55.2,"sd":null},{"arm":"IAI 2 mg Groups Combined (2Q16 & 2Q8)","deltaMin":58.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":89,"countries":["United States","Germany","Hungary","Japan","Puerto Rico","United Kingdom"]},"refs":{"pmids":["34351414"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":133},"commonTop":["Hypertension","Diabetic retinal oedema Study Eye","Diabetic retinal oedema Fellow Eye","Conjunctival haemorrhage Study Eye","Urinary tract infection"]}}